CA1335996C
(en)
*
|
1988-02-16 |
1995-06-20 |
Susumu Takada |
2-substituted carbonylimidazo¬4,5-c|quinolines
|
US5238944A
(en)
*
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
US5736553A
(en)
*
|
1988-12-15 |
1998-04-07 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
|
IL92537A
(en)
*
|
1988-12-15 |
1994-04-12 |
Riker Laboratories Inc |
Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
|
US5756747A
(en)
*
|
1989-02-27 |
1998-05-26 |
Riker Laboratories, Inc. |
1H-imidazo 4,5-c!quinolin-4-amines
|
CA2011504C
(en)
*
|
1989-03-07 |
1998-06-02 |
Kenji Ohmori |
Imidazoquinolone derivatives
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
US5037986A
(en)
*
|
1989-03-23 |
1991-08-06 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
|
NZ232740A
(en)
*
|
1989-04-20 |
1992-06-25 |
Riker Laboratories Inc |
Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
|
US4988815A
(en)
*
|
1989-10-26 |
1991-01-29 |
Riker Laboratories, Inc. |
3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
|
GB8928281D0
(en)
*
|
1989-12-14 |
1990-02-21 |
Smith Kline French Lab |
Compounds
|
DK0459505T3
(da)
*
|
1990-06-01 |
1996-11-18 |
Kyowa Hakko Kogyo Kk |
Imidazonaphthyridinderivater
|
DK0553202T3
(da)
*
|
1990-10-05 |
1995-07-03 |
Minnesota Mining & Mfg |
Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
|
US5389640A
(en)
*
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
WO1992015582A1
(en)
*
|
1991-03-01 |
1992-09-17 |
Minnesota Mining And Manufacturing Company |
1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
|
US5175296A
(en)
*
|
1991-03-01 |
1992-12-29 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
|
US5268376A
(en)
*
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5266575A
(en)
*
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
IL105325A
(en)
*
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
US6608201B2
(en)
|
1992-08-28 |
2003-08-19 |
3M Innovative Properties Company |
Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5395937A
(en)
*
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
US5648516A
(en)
*
|
1994-07-20 |
1997-07-15 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US5352784A
(en)
*
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
CZ288182B6
(en)
*
|
1993-07-15 |
2001-05-16 |
Minnesota Mining & Mfg |
Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
|
US5644063A
(en)
*
|
1994-09-08 |
1997-07-01 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-c]pyridin-4-amine intermediates
|
US5482936A
(en)
*
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
US5693811A
(en)
*
|
1996-06-21 |
1997-12-02 |
Minnesota Mining And Manufacturing Company |
Process for preparing tetrahdroimidazoquinolinamines
|
JP4391592B2
(ja)
|
1996-10-25 |
2009-12-24 |
スリーエム カンパニー |
Th2介在性および関連疾患治療のための免疫応答修飾化合物
|
US5939090A
(en)
|
1996-12-03 |
1999-08-17 |
3M Innovative Properties Company |
Gel formulations for topical drug delivery
|
EP0894797A4
(en)
*
|
1997-01-09 |
2001-08-16 |
Terumo Corp |
NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS
|
UA67760C2
(uk)
*
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
SI1040112T1
(en)
*
|
1997-12-11 |
2005-02-28 |
Minnesota Mining And Manufacturing Company |
Imidazonaphthyridines and their use in inducing cytokine biosynthesis
|
AU2002300984B2
(en)
*
|
1997-12-11 |
2004-12-02 |
Takeda Pharmaceutical Company Limited |
Imidazonaphthyridines and their use in inducing cytokine biosynthesis
|
US6312715B1
(en)
|
1998-05-01 |
2001-11-06 |
3M Innovative Properties Company |
Adhesive microsphere drug delivery composition
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
JP2000119271A
(ja)
*
|
1998-08-12 |
2000-04-25 |
Hokuriku Seiyaku Co Ltd |
1h―イミダゾピリジン誘導体
|
US6518280B2
(en)
*
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
ATE304852T1
(de)
*
|
1999-01-08 |
2005-10-15 |
3M Innovative Properties Co |
Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6573273B1
(en)
*
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
US6376669B1
(en)
*
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
US6894060B2
(en)
*
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
GB0023008D0
(en)
*
|
2000-09-20 |
2000-11-01 |
Glaxo Group Ltd |
Improvements in vaccination
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US6660747B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6667312B2
(en)
*
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
UA74593C2
(en)
*
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
EP1360486A2
(en)
*
|
2000-12-08 |
2003-11-12 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
AU2006216669A1
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
JP4331944B2
(ja)
*
|
2001-04-17 |
2009-09-16 |
大日本住友製薬株式会社 |
新規アデニン誘導体
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
US6893655B2
(en)
|
2001-10-09 |
2005-05-17 |
3M Innovative Properties Co. |
Transdermal delivery devices
|
JP2005519990A
(ja)
*
|
2001-10-12 |
2005-07-07 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
|
PT1719511E
(pt)
*
|
2001-11-16 |
2009-03-06 |
Coley Pharm Group Inc |
N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
|
NZ532769A
(en)
*
|
2001-11-29 |
2005-12-23 |
3M Innovative Properties Co |
Pharmaceutical formulations comprising an immune response modifier
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
CA2475595C
(en)
*
|
2002-02-22 |
2012-07-10 |
3M Innovative Properties Company |
Method of reducing and preventing uvb-induced immunosuppression
|
ATE491471T1
(de)
*
|
2002-03-19 |
2011-01-15 |
Powderject Res Ltd |
Adjuvantien für dns impstoffe basierend auf imidazochinoline
|
WO2003080112A2
(en)
*
|
2002-03-19 |
2003-10-02 |
Powdermed Limited |
Imidazoquinolineamines as adjuvants in hiv dna vaccination
|
IL164354A0
(en)
|
2002-04-04 |
2005-12-18 |
Coley Pharm Gmbh |
Immunostimulatory g,u-containing oligoribonucleotides
|
GB0211649D0
(en)
*
|
2002-05-21 |
2002-07-03 |
Novartis Ag |
Organic compounds
|
AU2003233519A1
(en)
|
2002-05-29 |
2003-12-19 |
3M Innovative Properties Company |
Process for imidazo(4,5-c)pyridin-4-amines
|
NZ537054A
(en)
*
|
2002-06-07 |
2006-10-27 |
3M Innovative Properties Co |
Ether substituted imidazopyridines
|
DK1543002T3
(da)
*
|
2002-07-23 |
2006-12-27 |
Teva Gyogyszergyar Zartkoeruee |
Fremstilling af 1H-imidazo (4,5-c) quinolin-4-aminer via 1H-imidazo (4,5-c) quinolin-4-phtalimid mellemprodukter
|
DK1539752T3
(da)
*
|
2002-07-26 |
2007-07-16 |
Teva Gyogyszergyar Zartkoeruee |
Fremstilling af 1H-imidazo(4,5-c)quinolin-4-aminer via ny imidazo(4,5-c)quinolin 4-cyano og 1H-imidazo(4,5-c)quinolin-4-carboxamid mellemprodukter
|
EP2269632B1
(en)
|
2002-08-15 |
2014-01-01 |
3M Innovative Properties Co. |
Immunostimulatory compositions and methods of stimulating an immune response
|
AU2003299082A1
(en)
*
|
2002-09-26 |
2004-04-19 |
3M Innovative Properties Company |
1h-imidazo dimers
|
CA2497765A1
(en)
*
|
2002-09-27 |
2004-04-08 |
Sumitomo Pharmaceuticals Co., Ltd. |
8-hydroxy substituted adenine compounds and uses thereof
|
AU2003287316A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
AU2003287324A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
NZ540826A
(en)
|
2002-12-20 |
2008-07-31 |
3M Innovative Properties Co |
Aryl / hetaryl substituted imidazoquinolines
|
AU2003300184B8
(en)
|
2002-12-30 |
2009-12-03 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
WO2004071459A2
(en)
*
|
2003-02-13 |
2004-08-26 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor 8
|
US7485432B2
(en)
*
|
2003-02-27 |
2009-02-03 |
3M Innovative Properties Company |
Selective modulation of TLR-mediated biological activity
|
US8110582B2
(en)
|
2003-03-04 |
2012-02-07 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
WO2004080398A2
(en)
*
|
2003-03-07 |
2004-09-23 |
3M Innovative Properties Company |
1-amino 1h-imidazoquinolines
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
CA2518082C
(en)
*
|
2003-03-13 |
2013-02-12 |
3M Innovative Properties Company |
Methods for diagnosing skin lesions
|
JP2006520245A
(ja)
*
|
2003-03-13 |
2006-09-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
入れ墨の除去方法
|
CA2518282C
(en)
*
|
2003-03-13 |
2012-11-06 |
3M Innovative Properties Company |
Methods of improving skin quality
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
EP1608369B1
(en)
|
2003-03-28 |
2013-06-26 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
EP1617871A4
(en)
*
|
2003-04-10 |
2010-10-06 |
3M Innovative Properties Co |
DISTRIBUTION OF IMMUNE-RESPONSE-MODIFYING COMPOUNDS USING PARTICULATE CARRIER MATERIALS CONTAINING METAL
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
WO2004110991A2
(en)
*
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
AR044466A1
(es)
*
|
2003-06-06 |
2005-09-14 |
3M Innovative Properties Co |
Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
|
US7521459B2
(en)
*
|
2003-07-28 |
2009-04-21 |
Metabeauty Inc. |
Method for treating damaged skin
|
KR20060054371A
(ko)
*
|
2003-07-31 |
2006-05-22 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
캡슐화 및 제어된 방출을 위한 조성물
|
US8211906B1
(en)
|
2003-08-05 |
2012-07-03 |
Scherrer Lawrence C |
Method of inhibiting growth of neoplastic cells and inhibiting infection by administering an immune enhancer drug
|
JP2007501252A
(ja)
*
|
2003-08-05 |
2007-01-25 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調整剤を含有する製剤
|
BRPI0412902A
(pt)
*
|
2003-08-12 |
2006-09-26 |
3M Innovative Properties Co |
compostos contendo imidazo substituìdo por oxima
|
CA2535338C
(en)
|
2003-08-14 |
2013-05-28 |
3M Innovative Properties Company |
Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
|
JP2007504145A
(ja)
*
|
2003-08-25 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫刺激性の組み合わせおよび治療
|
CA2536249A1
(en)
*
|
2003-08-25 |
2005-03-10 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
ES2406730T3
(es)
|
2003-08-27 |
2013-06-07 |
3M Innovative Properties Company |
Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
|
CA2536578A1
(en)
*
|
2003-09-02 |
2005-03-10 |
3M Innovative Properties Company |
Methods related to the treatment of mucosal associated conditions
|
CA2537763A1
(en)
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
WO2005029037A2
(en)
*
|
2003-09-17 |
2005-03-31 |
3M Innovative Properties Company |
Selective modulation of tlr gene expression
|
WO2005033049A2
(en)
*
|
2003-10-01 |
2005-04-14 |
Taro Pharmaceuticals U.S.A., Inc. |
METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
JP2007508305A
(ja)
|
2003-10-03 |
2007-04-05 |
スリーエム イノベイティブ プロパティズ カンパニー |
ピラゾロピリジンおよびその類似物
|
RU2412942C2
(ru)
|
2003-10-03 |
2011-02-27 |
3М Инновейтив Пропертиз Компани |
Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
|
JP2007509987A
(ja)
*
|
2003-10-31 |
2007-04-19 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節剤化合物による好中球活性化
|
WO2005047483A2
(en)
|
2003-11-12 |
2005-05-26 |
Medical Research Council |
Renta: an hiv immunogen and uses thereof
|
AU2004291101A1
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
EP1682544A4
(en)
|
2003-11-14 |
2009-05-06 |
3M Innovative Properties Co |
HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
|
AU2004293096A1
(en)
*
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
MY161812A
(en)
|
2003-11-25 |
2017-05-15 |
3M Innovative Properties Co |
Substituted imidazo ring systems and methods
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
WO2005055932A2
(en)
*
|
2003-12-02 |
2005-06-23 |
3M Innovative Properties Company |
Therapeutic combinations and methods including irm compounds
|
CN1914203A
(zh)
*
|
2003-12-04 |
2007-02-14 |
3M创新有限公司 |
砜取代的咪唑环醚
|
EP1701955A1
(en)
|
2003-12-29 |
2006-09-20 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
AU2004312510A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
|
AU2004312508A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
EP1699398A4
(en)
*
|
2003-12-30 |
2007-10-17 |
3M Innovative Properties Co |
IMPROVING THE IMMUNE RESPONSE
|
US20050201959A1
(en)
*
|
2004-03-11 |
2005-09-15 |
Vvii Newco 2003, Inc. |
Methods and compositions for altering skin coloration
|
CA2559607C
(en)
*
|
2004-03-15 |
2013-02-19 |
3M Innovative Properties Company |
Immune response modifier formulations and methods
|
AU2005228150A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
JPWO2005092892A1
(ja)
*
|
2004-03-26 |
2008-02-14 |
大日本住友製薬株式会社 |
8−オキソアデニン化合物
|
BRPI0509258A8
(pt)
|
2004-03-26 |
2019-01-22 |
Astrazeneca Ab |
composto de 8-oxoadenina 9-substituída
|
JP2007532572A
(ja)
*
|
2004-04-09 |
2007-11-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応調整剤を送達させるための方法、組成物および調製物
|
US20060051374A1
(en)
*
|
2004-04-28 |
2006-03-09 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
EP2811027A1
(en)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for RSV and PIV vaccines
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
WO2005123080A2
(en)
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US7884207B2
(en)
*
|
2004-06-18 |
2011-02-08 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
WO2006065280A2
(en)
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
US7897609B2
(en)
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
ITMI20041282A1
(it)
*
|
2004-06-24 |
2004-09-24 |
Dipharma Spa |
Procedimento per la preparazione di imiquimod
|
JP2008504292A
(ja)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
免疫増強用の化合物
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
EP1786450A4
(en)
*
|
2004-08-27 |
2009-11-11 |
3M Innovative Properties Co |
HIV IMMUNOSTIMATORY COMPOSITIONS
|
WO2006029115A2
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
CA2578741C
(en)
*
|
2004-09-02 |
2014-01-14 |
3M Innovative Properties Company |
1-alkoxy 1h-imidazo ring systems and methods
|
WO2006031878A2
(en)
*
|
2004-09-14 |
2006-03-23 |
Novartis Vaccines And Diagnostics Inc. |
Imidazoquinoline compounds
|
WO2006042254A2
(en)
*
|
2004-10-08 |
2006-04-20 |
3M Innovative Properties Company |
Adjuvant for dna vaccines
|
US8080560B2
(en)
*
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
AU2004326103A1
(en)
*
|
2004-12-27 |
2006-07-06 |
Usv Limited |
A process for preparation of 4-Amino-1-isobutyl-1H-imidazo[4,5-c]-quinoline (Imiquimod)
|
JP2008526765A
(ja)
|
2004-12-30 |
2008-07-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
皮膚転移の処置
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
JP5543068B2
(ja)
|
2004-12-30 |
2014-07-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
|
AU2005326708C1
(en)
|
2004-12-30 |
2012-08-30 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
NZ556399A
(en)
*
|
2004-12-30 |
2009-03-31 |
Takeda Pharmaceutical |
1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate
|
US9248127B2
(en)
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
CA2602083A1
(en)
|
2005-02-09 |
2006-08-09 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
|
AU2006212765B2
(en)
|
2005-02-09 |
2012-02-02 |
3M Innovative Properties Company |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US7968563B2
(en)
|
2005-02-11 |
2011-06-28 |
3M Innovative Properties Company |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
CA2597446A1
(en)
*
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
WO2006089264A2
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
CN101180312A
(zh)
|
2005-02-18 |
2008-05-14 |
诺华疫苗和诊断公司 |
来自尿路病原性大肠杆菌的免疫原
|
CA2598437A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
CA2598695A1
(en)
|
2005-02-23 |
2006-09-21 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinolines
|
EP1851220A2
(en)
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazonaphthyridines
|
WO2006091567A2
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
WO2006099275A2
(en)
*
|
2005-03-14 |
2006-09-21 |
3M Innovative Properties Company |
Method of treating actinic keratosis
|
BRPI0609399A2
(pt)
*
|
2005-03-21 |
2010-03-30 |
Ferrer Int |
método para produzir compostos da 1h-imidazo[4,5-c]quinolin-4-amina 1-substituìda e intermediários dos mesmos
|
EP1869043A2
(en)
|
2005-04-01 |
2007-12-26 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
EP1863814A1
(en)
|
2005-04-01 |
2007-12-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
EP1874345B1
(en)
*
|
2005-04-25 |
2012-08-15 |
3M Innovative Properties Company |
Immunostimulatory compositions
|
US20100017895A1
(en)
|
2005-07-18 |
2010-01-21 |
Amy Weiner |
Small animal model for hcv replication
|
CN101304748A
(zh)
|
2005-08-22 |
2008-11-12 |
加利福尼亚大学董事会 |
Tlr激动剂
|
AU2006287270A1
(en)
|
2005-09-09 |
2007-03-15 |
Coley Pharmaceutical Group, Inc. |
Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
US8889154B2
(en)
|
2005-09-15 |
2014-11-18 |
Medicis Pharmaceutical Corporation |
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
|
TW200801003A
(en)
*
|
2005-09-16 |
2008-01-01 |
Astrazeneca Ab |
Novel compounds
|
TW200745114A
(en)
*
|
2005-09-22 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
US20090118263A1
(en)
*
|
2005-09-22 |
2009-05-07 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel Adenine Compound
|
JPWO2007034917A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規なアデニン化合物
|
US20080269240A1
(en)
|
2005-09-22 |
2008-10-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel Adenine Compound
|
US20090099216A1
(en)
*
|
2005-09-22 |
2009-04-16 |
Astrazeneca Aktiebolag A Corporation Of Sweden |
Novel adenine compound
|
EP1939198A4
(en)
*
|
2005-09-22 |
2012-02-15 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
US20070081962A1
(en)
*
|
2005-10-06 |
2007-04-12 |
Amit Munshi |
Novel delivery of immune response modifiers for removal of chronic tattoos
|
US7629027B2
(en)
*
|
2005-10-14 |
2009-12-08 |
3M Innovative Properties Company |
Method for making chromonic nanoparticles
|
US7718716B2
(en)
*
|
2005-10-14 |
2010-05-18 |
3M Innovative Properties Company |
Chromonic nanoparticles containing bioactive compounds
|
US20110223197A1
(en)
|
2005-10-18 |
2011-09-15 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and Systemic Immunization with Alphavirus Replicon Particles
|
US20070100146A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Trevor Dzwiniel |
Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
|
CA2628131C
(en)
|
2005-11-04 |
2012-03-20 |
Coley Pharmaceutical Group, Inc. |
Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
|
EP2368572B1
(en)
|
2005-11-04 |
2020-03-04 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
EP1951298A1
(en)
|
2005-11-04 |
2008-08-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
NZ567978A
(en)
|
2005-11-04 |
2011-09-30 |
Novartis Vaccines & Diagnostic |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
JP5215865B2
(ja)
|
2005-11-22 |
2013-06-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
ノロウイルス抗原およびサポウイルス抗原
|
US20070128291A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Tokie Jeffrey H |
Method and Apparatus for Forming Chromonic Nanoparticles
|
US7807661B2
(en)
*
|
2005-12-08 |
2010-10-05 |
3M Innovative Properties Company |
Silver ion releasing articles and methods of manufacture
|
US7323568B2
(en)
*
|
2005-12-12 |
2008-01-29 |
Chemagis Ltd. |
Process for preparing Imiquimod
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PT2478916T
(pt)
|
2006-01-27 |
2020-07-03 |
Seqirus Uk Ltd |
Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
US8329721B2
(en)
|
2006-03-15 |
2012-12-11 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
|
US8088788B2
(en)
|
2006-03-15 |
2012-01-03 |
3M Innovative Properties Company |
Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
WO2007109810A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
EP2382987A1
(en)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Storage of influenza vaccines without refrigeration
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
WO2007121491A1
(en)
*
|
2006-04-25 |
2007-11-01 |
Intercell Ag |
Hcv vaccinations
|
US20070275185A1
(en)
*
|
2006-05-23 |
2007-11-29 |
3M Innovative Properties Company |
Method of making ordered nanostructured layers
|
CA2653941C
(en)
|
2006-05-31 |
2013-01-08 |
The Regents Of The University Of California |
Substituted amino purine derivatives and uses thereof
|
CA2654324A1
(en)
|
2006-06-02 |
2007-12-13 |
International Aids Vaccine Initiative |
Hiv-1 clade a consensus sequences, antigens, and transgenes
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
WO2007147529A2
(en)
|
2006-06-20 |
2007-12-27 |
Transgene S.A. |
Recombinant viral vaccine
|
JP2009542645A
(ja)
*
|
2006-07-05 |
2009-12-03 |
アストラゼネカ・アクチエボラーグ |
Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体
|
US20090238763A1
(en)
|
2006-07-09 |
2009-09-24 |
Chongxi Yu |
High penetration compositions and uses thereof
|
US20090221703A1
(en)
|
2006-07-09 |
2009-09-03 |
Chongxi Yu |
High penetration composition and uses thereof
|
WO2008008432A2
(en)
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
|
US9023863B2
(en)
|
2006-07-14 |
2015-05-05 |
Stiefel Research Australia Pty Ltd |
Fatty acid pharmaceutical foam
|
WO2008010963A2
(en)
*
|
2006-07-18 |
2008-01-24 |
3M Innovative Properties Company |
Immune response modifier formulations
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
US8124096B2
(en)
*
|
2006-07-31 |
2012-02-28 |
3M Innovative Properties Company |
Immune response modifier compositions and methods
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
WO2008023333A2
(en)
*
|
2006-08-22 |
2008-02-28 |
Ranbaxy Laboratories Limited |
Process for the preparation of 4-(isobutylamino)-3-amino-quinoline
|
US8178539B2
(en)
|
2006-09-06 |
2012-05-15 |
3M Innovative Properties Company |
Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
|
EP3456348A1
(en)
|
2006-09-11 |
2019-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
US20080103310A1
(en)
*
|
2006-10-16 |
2008-05-01 |
Janos Hajko |
Preparation of 1H-imidazo[4,5-c]quinolin-4-amines via 1H-imidazo[4, 5-c]quinolin-4-phtalimide intermediates
|
ES2480491T3
(es)
|
2006-12-06 |
2014-07-28 |
Novartis Ag |
Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
|
TW200831105A
(en)
*
|
2006-12-14 |
2008-08-01 |
Astrazeneca Ab |
Novel compounds
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
US7943771B2
(en)
*
|
2007-01-24 |
2011-05-17 |
Chemagis Ltd. |
Imiquimod production process
|
CN106432226B
(zh)
*
|
2007-01-31 |
2019-08-30 |
于崇曦 |
1H-咪唑并[4,5-c]喹啉-4-胺类及其相关化合物的前药
|
AU2007345952C1
(en)
*
|
2007-01-31 |
2017-06-08 |
Chongxi Yu |
Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
|
BRPI0807196A2
(pt)
|
2007-02-07 |
2014-06-03 |
Univ California |
Método para prevenir ou inibir uma infecção bacteriana, vacina, composto, e, método para prevenir, tratar ou inibir a asma
|
US7659398B2
(en)
*
|
2007-02-14 |
2010-02-09 |
Chemagis Ltd. |
Imiquimod production process
|
EP1958613A1
(en)
*
|
2007-02-15 |
2008-08-20 |
Polichem S.A. |
Dermal film-forming liquid formulations for drug release to skin
|
ATE530549T1
(de)
*
|
2007-03-19 |
2011-11-15 |
Astrazeneca Ab |
9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7)
|
EP2132209B8
(en)
*
|
2007-03-19 |
2014-04-16 |
AstraZeneca AB |
9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
|
PE20081887A1
(es)
*
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Nuevo compuesto de adenina
|
JPWO2008114819A1
(ja)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
US20080280943A1
(en)
*
|
2007-03-23 |
2008-11-13 |
Slade Herbert B |
Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
|
WO2008118763A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Graceway Pharmaceuticals, Llc. |
Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
|
WO2008118765A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Graceway Pharmaceuticals, Llc |
Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
|
JP5400763B2
(ja)
*
|
2007-05-08 |
2014-01-29 |
アストラゼネカ・アクチエボラーグ |
免疫調節特性を有するイミダゾキノリン類
|
KR101853971B1
(ko)
|
2007-06-04 |
2018-05-02 |
테크필즈 인크 |
매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(nsaia) 약물전구체 및 이들의 새로운 의약적 용도
|
EP2484377A1
(en)
|
2007-06-27 |
2012-08-08 |
Novartis AG |
Low-additive influenza vaccines
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
AU2008299376B2
(en)
|
2007-09-12 |
2013-02-28 |
Glaxosmithkline Biologicals S.A. |
GAS57 mutant antigens and GAS57 antibodies
|
PE20091236A1
(es)
*
|
2007-11-22 |
2009-09-16 |
Astrazeneca Ab |
Derivados de pirimidina como immunomoduladores de tlr7
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
PE20091156A1
(es)
|
2007-12-17 |
2009-09-03 |
Astrazeneca Ab |
Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
|
PE20091523A1
(es)
|
2007-12-20 |
2009-10-29 |
Novartis Ag |
Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
KR101773114B1
(ko)
|
2007-12-21 |
2017-08-30 |
노파르티스 아게 |
스트렙토라이신 o의 돌연변이 형태
|
WO2009091541A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Dow Pharmaceutical Sciences, Inc. |
Imiquimod formulation
|
EA201001264A1
(ru)
*
|
2008-02-07 |
2011-04-29 |
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния |
Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
|
NZ588191A
(en)
|
2008-03-03 |
2012-06-29 |
Irm Llc |
Compounds and compositions as tlr activity modulators
|
KR20100135766A
(ko)
|
2008-03-18 |
2010-12-27 |
노파르티스 아게 |
인플루엔자 바이러스 백신 항원 제조의 개선
|
US20100160368A1
(en)
*
|
2008-08-18 |
2010-06-24 |
Gregory Jefferson J |
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
|
BRPI0922263B1
(pt)
|
2008-12-04 |
2021-08-31 |
Chongxi Yu |
Composição de alta penetração de um fármaco principal, e seus usos
|
EA201100984A1
(ru)
|
2008-12-19 |
2012-01-30 |
Грэйсуэй Фармасьютикалс, Ллс |
Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения актинического кератоза
|
AU2010204139A1
(en)
|
2009-01-12 |
2011-08-11 |
Novartis Ag |
Cna_B domain antigens in vaccines against gram positive bacteria
|
PT2382474E
(pt)
|
2009-01-20 |
2015-06-03 |
Transgene Sa |
Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
|
WO2010088924A1
(en)
|
2009-02-06 |
2010-08-12 |
Telormedix Sa |
Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
|
MX2011008500A
(es)
*
|
2009-02-11 |
2011-09-26 |
Univ California |
Moduladores del receptor tipo toll y tratamiento de enfermedades.
|
EP2403526B1
(en)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia antigens
|
MX2011010061A
(es)
|
2009-03-24 |
2011-11-18 |
Transgene Sa |
Biomarcador para monitorear pacientes.
|
MX2011010050A
(es)
|
2009-03-25 |
2011-12-14 |
Univ Texas |
Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
MX2011010920A
(es)
|
2009-04-17 |
2011-11-04 |
Transgene Sa |
Biomarcador para monitorear pacientes.
|
KR20120027276A
(ko)
|
2009-04-27 |
2012-03-21 |
노파르티스 아게 |
인플루엔자를 예방하기 위한 면역증강된 백신
|
GB0908772D0
(en)
*
|
2009-05-21 |
2009-07-01 |
Astrazeneca Ab |
New salts 756
|
MX2011012337A
(es)
|
2009-05-21 |
2011-12-08 |
Dainippon Sumitomo Pharma Co |
Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
NZ596325A
(en)
|
2009-07-10 |
2013-11-29 |
Transgene Sa |
Biomarker for selecting patients and related methods
|
EP2453747B1
(en)
*
|
2009-07-13 |
2017-08-30 |
Medicis Pharmaceutical Corporation |
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
|
HRP20220756T1
(hr)
|
2009-07-15 |
2022-09-02 |
Glaxosmithkline Biologicals S.A. |
Proteinski pripravci rsv f i postupci za izradu istih
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
SG170622A1
(en)
|
2009-10-09 |
2011-05-30 |
Nitto Denko Corp |
A passive drug delivery device and a method of drug delivery
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
EP2550362B1
(en)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US20110319811A1
(en)
|
2010-06-25 |
2011-12-29 |
Nordsiek Michael T |
Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
US9072876B2
(en)
|
2010-08-05 |
2015-07-07 |
Medicis Pharmaceutical Corporation |
Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
|
US9242980B2
(en)
|
2010-08-17 |
2016-01-26 |
3M Innovative Properties Company |
Lipidated immune response modifier compound compositions, formulations, and methods
|
EP2651937B8
(en)
|
2010-12-16 |
2016-07-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
|
JP5978226B2
(ja)
|
2010-12-17 |
2016-08-24 |
大日本住友製薬株式会社 |
プリン誘導体
|
EP4159232A1
(en)
|
2011-01-26 |
2023-04-05 |
GlaxoSmithKline Biologicals S.A. |
Rsv immunization regimen
|
UY33883A
(es)
|
2011-01-31 |
2012-08-31 |
Novartis Ag |
Novedosos derivados heterocíclicos
|
WO2012149038A1
(en)
|
2011-04-25 |
2012-11-01 |
Advanced Bioscience Laboratories, Inc. |
Truncated hiv envelope proteins (env), methods and compositions related thereto
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
JP6415979B2
(ja)
|
2011-06-03 |
2018-10-31 |
スリーエム イノベイティブ プロパティズ カンパニー |
ヒドラジノ1h−イミダゾキノリン−4−アミン及びこれから調製された複合体
|
MX347240B
(es)
|
2011-06-03 |
2017-04-20 |
3M Innovative Properties Co |
Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
|
CA2832109C
(en)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
EP3332802A1
(en)
|
2011-07-06 |
2018-06-13 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
JP2014520807A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
免疫原性組成物およびその使用
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
WO2013040447A2
(en)
|
2011-09-14 |
2013-03-21 |
Medicis Pharmaceutical Corporation |
Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
|
WO2013041247A1
(en)
|
2011-09-23 |
2013-03-28 |
Westfällsche Wilhelms-Universitaet Muenster |
Yersinia outer protein m (yopm) in the treatment of psoriasis induced by imiquimod
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
MX354924B
(es)
|
2011-11-07 |
2018-03-22 |
Novartis Ag |
Molecula portadora que comprende un antigeno spr0096 y un spr2021.
|
WO2013093629A2
(en)
|
2011-12-20 |
2013-06-27 |
Netherlands Cancer Institute |
Modular vaccines, methods and compositions related thereto
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
US9347065B2
(en)
|
2012-03-29 |
2016-05-24 |
International Aids Vaccine Initiative |
Methods to improve vector expression and genetic stability
|
AU2013252785B2
(en)
|
2012-04-27 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
|
KR20200075023A
(ko)
|
2012-05-04 |
2020-06-25 |
화이자 인코포레이티드 |
전립선 관련된 항원 및 백신 기재 면역치료 요법
|
US10213432B2
(en)
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
JP6184423B2
(ja)
|
2012-05-18 |
2017-08-23 |
大日本住友製薬株式会社 |
カルボン酸化合物
|
EP2674170B1
(en)
|
2012-06-15 |
2014-11-19 |
Invivogen |
Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
MX2014015769A
(es)
|
2012-06-29 |
2015-04-10 |
Pfizer |
7h-pirrolo[2,3-d]pirimidinas 4-(amino-substituidas)novedosas como inhibidores de lrrk2.
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
WO2014040025A2
(en)
|
2012-09-10 |
2014-03-13 |
International Aids Vaccine Initiative |
Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
|
CN104736091A
(zh)
|
2012-09-21 |
2015-06-24 |
3M创新有限公司 |
切口保护
|
EP2912047B1
(en)
|
2012-10-29 |
2016-08-24 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
EP2730271B1
(en)
|
2012-11-11 |
2018-01-24 |
Symrise AG |
Aqeuous compositions
|
EP2732825B1
(en)
|
2012-11-19 |
2015-07-01 |
Invivogen |
Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
|
HUE051988T2
(hu)
|
2013-01-07 |
2021-04-28 |
Univ Pennsylvania |
Készítmények és eljárások bõr T-sejt lymphoma kezelésére
|
EP2769738B1
(en)
|
2013-02-22 |
2016-07-20 |
Invivogen |
Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
|
US9295732B2
(en)
|
2013-02-22 |
2016-03-29 |
Invivogen |
Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
|
ES2701758T3
(es)
|
2013-02-27 |
2019-02-25 |
Symrise Ag |
Extracto de jengibre para la protección de citoblastos
|
US9072747B2
(en)
|
2013-03-10 |
2015-07-07 |
Peritech Pharma Ltd. |
Topical compositions and methods of treatment of anorectal disorders
|
WO2014201245A1
(en)
|
2013-06-12 |
2014-12-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
|
EP3024476A1
(en)
|
2013-07-26 |
2016-06-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
EP2862852B1
(en)
|
2013-10-18 |
2018-07-04 |
Symrise AG |
Urea derivatives for the protection of stem cells
|
AU2014347059B2
(en)
|
2013-11-05 |
2017-09-07 |
Solventum Intellectual Properties Company |
Sesame oil based injection formulations
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
JP2016539149A
(ja)
|
2013-12-06 |
2016-12-15 |
ノバルティス アーゲー |
アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
WO2015092592A1
(en)
|
2013-12-17 |
2015-06-25 |
Pfizer Inc. |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
CN114716555A
(zh)
|
2014-01-10 |
2022-07-08 |
博笛生物科技有限公司 |
靶向表达egfr的肿瘤的化合物和组合物
|
US10421971B2
(en)
|
2014-01-15 |
2019-09-24 |
The University Of Chicago |
Anti-tumor therapy
|
EP2921157B1
(en)
|
2014-03-18 |
2017-08-16 |
Symrise AG |
Coated titanium dioxide to reduce whitening effect on skin
|
SI3122378T1
(sl)
|
2014-03-26 |
2020-03-31 |
Glaxosmithkline Biologicals S.A. |
Mutantni stafilokokni antigeni
|
ES2819207T3
(es)
|
2014-04-29 |
2021-04-15 |
Symrise Ag |
Mezclas activas
|
WO2015171975A1
(en)
|
2014-05-09 |
2015-11-12 |
The Regents Of The University Of Michigan |
Use of modified banana lectin in purification of glycoproteins
|
US10093720B2
(en)
|
2014-06-11 |
2018-10-09 |
International Aids Vaccine Initiative |
Broadly neutralizing antibody and uses thereof
|
AU2015286043B2
(en)
|
2014-07-09 |
2020-08-20 |
Birdie Biopharmaceuticals Inc. |
Anti-PD-L1 combinations for treating tumors
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于***的抗-pd-l1结合物
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
FR3031105B1
(fr)
|
2014-12-31 |
2018-04-06 |
Universite De Montpellier |
Nouveaux imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers
|
EP3045161A1
(en)
|
2015-01-18 |
2016-07-20 |
Symrise AG |
Active compositions comprising 1,2-hexanediol and 1,2-octanediol
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
WO2016183371A1
(en)
|
2015-05-13 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for the treatment or prevention of ischemic tissue damage
|
EP3344623B1
(en)
|
2015-08-31 |
2021-02-17 |
3M Innovative Properties Company |
Imidazo[4,5-c]ring compounds containing substituted guanidine groups
|
MX2018002017A
(es)
|
2015-08-31 |
2018-03-26 |
3M Innovative Properties Co |
Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina.
|
EP3347047A1
(en)
|
2015-09-09 |
2018-07-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expression vector delivery system and use thereof for inducing an immune response
|
WO2017046675A1
(en)
*
|
2015-09-14 |
2017-03-23 |
Pfizer Inc. |
Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
|
US10597397B2
(en)
|
2015-09-29 |
2020-03-24 |
Sumitomo Dainippon Pharma Co., Ltd. |
Adenine conjugate compounds and their use as vaccine adjuvants
|
US9925258B2
(en)
|
2015-10-02 |
2018-03-27 |
International Aids Vaccine Initiative |
Replication-competent VSV-HIV Env vaccines
|
US10526309B2
(en)
|
2015-10-02 |
2020-01-07 |
The University Of North Carolina At Chapel Hill |
Pan-TAM inhibitors and Mer/Axl dual inhibitors
|
HUE064322T2
(hu)
|
2015-10-07 |
2024-03-28 |
Sumitomo Pharma Co Ltd |
Pirimidin vegyületet és patogén eredetû antigént tartalmazó készítmény
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于***的抗-her2组合
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于***的抗-cd20组合
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于***的抗-egfr组合
|
US11191821B2
(en)
|
2016-02-27 |
2021-12-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccine formulations and use thereof for inducing an immune response
|
WO2017184735A1
(en)
*
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Nlrp3 modulators
|
IL313085A
(en)
|
2016-05-16 |
2024-07-01 |
Access To Advanced Health Inst |
Pegylated liposomes and methods of use
|
IL299285A
(en)
|
2016-05-16 |
2023-02-01 |
Access To Advanced Health Inst |
Formulation containing a TLR agonist and methods of use
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
KR20230149857A
(ko)
|
2016-07-07 |
2023-10-27 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항체-애쥬번트 접합체
|
EP3504215B1
(en)
|
2016-08-26 |
2022-04-06 |
3M Innovative Properties Company |
Fused [1,2]imidazo[4,5-c]ring compounds substituted with guanidino groups
|
CA3033542A1
(en)
|
2016-08-30 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Compositions and uses of biomaterials and activators of innate immunity
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
WO2018085066A1
(en)
|
2016-11-03 |
2018-05-11 |
3M Innovative Properties Company |
Silicone copolymers, methods of making, and articles
|
US11826422B2
(en)
|
2016-11-09 |
2023-11-28 |
Board Of Regents, The University Of Texas System |
Methods and compositions for adaptive immune modulation
|
CA3045517A1
(en)
|
2016-12-05 |
2018-06-14 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
WO2018160552A1
(en)
|
2017-03-01 |
2018-09-07 |
3M Innovative Properties Company |
IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
|
SG10202110112TA
(en)
*
|
2017-03-10 |
2021-10-28 |
Pfizer |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
WO2018181420A1
(ja)
|
2017-03-29 |
2018-10-04 |
大日本住友製薬株式会社 |
ワクチンアジュバント製剤
|
CN110650750A
(zh)
|
2017-04-04 |
2020-01-03 |
阿维迪科技公司 |
基于肽的疫苗、其制造方法及其用于诱导免疫应答的用途
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
DK3625231T3
(da)
*
|
2017-05-19 |
2022-10-31 |
Superb Wisdom Ltd |
Derivatives of resiquimod
|
MX2019015744A
(es)
|
2017-06-23 |
2020-02-20 |
Birdie Biopharmaceuticals Inc |
Composiciones farmaceuticas.
|
EP4257198A3
(en)
|
2017-08-22 |
2023-10-18 |
Dynavax Technologies Corporation |
Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
|
WO2019099412A1
(en)
|
2017-11-14 |
2019-05-23 |
Dynavax Technologies Corporation |
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
US11306083B2
(en)
|
2017-12-20 |
2022-04-19 |
3M Innovative Properties Company |
Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
CA3085424A1
(en)
|
2017-12-21 |
2019-06-27 |
Sumitomo Dainippon Pharma Co., Ltd. |
Combination drug including tlr7 agonist
|
CN111788202B
(zh)
*
|
2018-02-28 |
2024-03-01 |
3M创新有限公司 |
具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物
|
BR112020016859A2
(pt)
|
2018-02-28 |
2020-12-29 |
Pfizer Inc. |
Variantes de il-15 e usos da mesma
|
WO2019226828A2
(en)
|
2018-05-22 |
2019-11-28 |
Avidea Technologies, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
BR112020022595A2
(pt)
|
2018-05-23 |
2021-02-09 |
Pfizer Inc. |
anticorpos específicos para gucy2c e usos dos mesmos
|
BR112020022897A2
(pt)
|
2018-05-23 |
2021-02-23 |
Pfizer Inc. |
anticorpos específicos para cd3 e usos dos mesmos
|
US11884662B2
(en)
|
2018-05-24 |
2024-01-30 |
3M Innovative Properties Company |
N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
SG11202011587PA
(en)
|
2018-05-30 |
2020-12-30 |
Translate Bio Inc |
Messenger rna vaccines and uses thereof
|
CN112513031A
(zh)
|
2018-06-04 |
2021-03-16 |
阿普罗斯治疗公司 |
可用于治疗与tlr7调节相关的疾病的含酸性基团的嘧啶化合物
|
KR20210034614A
(ko)
|
2018-07-23 |
2021-03-30 |
국립감염증연구소장이 대표하는 일본국 |
인플루엔자 백신을 포함하는 조성물
|
US20210353740A1
(en)
|
2018-09-23 |
2021-11-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
|
EP3860646A1
(en)
|
2018-10-03 |
2021-08-11 |
Avidea Technologies, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
EP3887369B1
(en)
|
2018-11-26 |
2024-05-08 |
Solventum Intellectual Properties Company |
N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
EP3937984A1
(en)
|
2019-03-15 |
2022-01-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
JP2022529183A
(ja)
|
2019-04-17 |
2022-06-17 |
アヴィディア テクノロジーズ, インコーポレイテッド |
リガンド提示および/または薬物送達のためのスターポリマーを製造する組成物および方法
|
EP3980415A1
(en)
|
2019-06-06 |
2022-04-13 |
3M Innovative Properties Company |
N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
CN113906027A
(zh)
*
|
2019-06-12 |
2022-01-07 |
3M创新有限公司 |
具有N-1支链基团的苯乙基取代的咪唑并[4,5-c]喹啉化合物
|
AU2020310853A1
(en)
|
2019-07-05 |
2022-01-27 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
WO2021116420A1
(en)
|
2019-12-13 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
|
EP4077387A1
(en)
|
2019-12-17 |
2022-10-26 |
Pfizer Inc. |
Antibodies specific for cd47, pd-l1, and uses thereof
|
TW202146427A
(zh)
|
2020-02-21 |
2021-12-16 |
美商國際愛滋病疫苗開發股份有限公司 |
用於預防冠狀病毒疾病的疫苗組合物
|
US20230165723A1
(en)
|
2020-04-30 |
2023-06-01 |
Kindeva Drug Delivery L.P. |
Adhesive article and method of making same
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
WO2022032191A1
(en)
|
2020-08-07 |
2022-02-10 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
FR3113287B1
(fr)
|
2020-08-07 |
2023-06-23 |
Phv Pharma |
Procédé industriel de synthèse de l’imiquimod à partir de la quinolèine-2,4-diol applicable à son utilisation pharmaceutique
|
WO2022066635A1
(en)
|
2020-09-22 |
2022-03-31 |
Avidea Technologies, Inc. |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
WO2022086853A1
(en)
|
2020-10-19 |
2022-04-28 |
Avidea Technologies, Inc. |
Star polymer drug conjugates
|
JP2023552993A
(ja)
*
|
2020-12-09 |
2023-12-20 |
ウェルスタット セラピューティクス コーポレイション |
抗炎症作用、抗真菌作用、抗寄生虫作用、及び抗がん作用を有するイミダゾキノリン化合物
|
AU2022224567A1
(en)
|
2021-02-16 |
2023-08-24 |
Barinthus Biotherapeutics North America, Inc. |
Self-assembling nanoparticles based on amphiphilic peptides
|
ES2940736B2
(es)
|
2021-11-09 |
2023-09-19 |
Ntd Labs S L U |
Uso combinado de imiquimod y de un hidrolizado de caseina para el tratamiento de condilomas
|
WO2024092030A1
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Self-assembling nanoparticles
|
WO2024092028A2
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Combination treatment regimes for treating cancer
|